iVexSol announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (BMY), Charles River Laboratories (CRL) and Asahi Kasei Medical, a division of Asahi Kasei (AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (BLFS) to close Series A financing at a total of more than $39 million. The new funding will be used to invest in iVexSol’s Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers reports TRANSCEND CLL 004 trial of Breyanzi met primary endpoint
- Celgene treatment of follicular lymphoma granted FDA orphan designation
- Truist healthcare analysts to hold an analyst/industry conference call
- Amgen price target cut at Piper on lower Otezla estimates
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations